There were a lot of bummed out investors when VANC Pharmaceuticals rolled back their share base recently, but the dip has brought about a very interesting last 48 hours as, according to information we’ve been hearing, a fight for board control has sent the stock soaring.

After an extended period at around $0.19, VANC shares have flown over the last few days, topping at $0.47 before settling in around $0.41 at the time of writing. That’s a 115% increase.

Happy long time holders are in the dark as to what’s going on, but we hear a group of shareholders have taken advantage of the lower price to position themselves for a run at the board.

Can’t say whether the activity will continue or not, but volume appeared to surge at 11am Wednesday when the price topped out. Best guess is the buyers will wait and see how many bagholders sell up before maybe making another run if prices sag once more.

VANC was most recently in the news when it announced, in early December, that it was looking to acquire HealthTab, an in-pharmacy pin-prick health analytics system.

VANC Pharma’s business model is to supply low cost generic treatments and products to the healthcare space, such as Hema-Fer, CortiVera and VanFer.

— Chris Parry

Written By:

Chris Parry

A multi-Webster Award winner for excellence in BC journalism, Parry is the founder and publisher of Equity.Guru, which he built with the specific plan to blend old school reporting with stock promotion, in a way that puts the emphasis on truth, high standards, and ethics. Parry is a veteran of TV, radio, and print, and consults with public companies to help them figure out their storylines, lay down achievable milestones, and improve their communication with shareholders, while also posting regular deep dive analysis of companies in the public spotlight.

More By This Author
Health Science
Vanc Pharmaceuticals
0 0 votes
Article Rating
Notify of
Inline Feedbacks
View all comments
Would love your thoughts, please comment.x